Forecast

The analysts' average price target is +16,74€ (+1,52%). The median is +16,74€ (+1,52%).

Buy	4
Hold	10
Sell	0

News Go to news feed

Kenvue raises quarterly dividend by 1.2% to $0.21

Kenvue has increased the quarterly dividend by 1.2% to $0.21 per common share. The payment will be made on August 26, 2026, to shareholders of record on August 12, 2026. Kenvue operates in the consumer health sector and owns brands such as Aveeno, BAND-AID, Johnson’s, Listerine, Neutrogena and Tylenol. » More on de.investing.com
Federal appeals court reinstates Tylenol lawsuits against Kenvue — stock falls

A three-judge panel in New York vacated the dismissal of suits against Kenvue and sent the case back for further proceedings, saying the lower court apparently exceeded its discretion when excluding three expert witnesses. Plaintiffs accuse Kenvue of concealing risks of a link between Tylenol use during pregnancy and autism; in 2023 about 500 suits had already been partly dismissed. Resuming the cases could lead to thousands more filings; a potential settlement could cost billions, Bloomberg Intelligence says. Kenvue shares fell about 1% on Monday. » More on de.investing.com
Kenvue: options trading picks up, calls dominate volume

Options volume on Kenvue rose sharply to 14,072 contracts, of which 12,948 were calls. Notably, the $20 call expiring July 17, 2026 accounted for 11,206 contracts. A put spread for August and several call spreads between August 2026 and February 2027 also saw activity. The stock traded at $19.55 (+1.93%), and three-month volatility fell to 22.51%. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Kenvue has already paid 0,54€ in dividends. The last payout was in August.

Financials

In the last quarter, Kenvue had revenue of 3.47b€ and net profit of 400.49m€

(EUR)	Jun 2026	YoY
Revenue	+3.47b	6,10%
Gross profit	+2.02b	4,81%
Net profit	+400.49m	11,82%
EBITDA	+731.59m	2,50%

Fundamentals

Metric	Value
Market capitalization	+31.69b€
Number of shares	1.92b
52-week high/low	+17,99€ - +12,04€
Dividend yield	+4,30%
Dividends TTM	+0,71€
Beta	0,43
P/E ratio	+22,09
PEG ratio	+1,26
P/B ratio	+3,50
P/S ratio	+2,40

Company profile

Kenvue Inc. ist ein weltweit tätiges Unternehmen im Bereich der Verbrauchergesundheit. Das Unternehmen ist in drei Segmenten tätig: Self Care, Skin Health and Beauty und Essential Health. Das Segment Self Care bietet unter den Marken Tylenol, Nicorette und Zyrtec Produkte zur Behandlung von Husten, Erkältungen und Allergien, zur Schmerzbehandlung, für die Verdauung, zur Raucherentwöhnung und andere Produkte an. Das Segment Skin Health and Beauty bietet unter den Markennamen Neutrogena, Aveeno und OGX Gesichts- und Körperpflege, Haarpflege sowie Sonnen- und andere Pflegeprodukte an. Das Segment Essential Health bietet unter den Marken Listerine, Johnson's, Band-Aid und Stayfree Produkte für die Mund- und Babypflege, die Gesundheit von Frauen und die Wundpflege an. Das Unternehmen wurde im Jahr 2022 gegründet und hat seinen Hauptsitz in Skillman, New Jersey. Kenvue Inc. arbeitet als Tochtergesellschaft von Johnson & Johnson.

Name	Kenvue
CEO	Kirk L. Perry
Headquarters	Summit, nj USA
Website	kenvue.com
Sector	Consumer Staples
Industry	Consumer Staples Distribution & Retail
IPO	05/04/2023
Employees	21.890